BR112017012142A2 - método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama - Google Patents

método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama

Info

Publication number
BR112017012142A2
BR112017012142A2 BR112017012142A BR112017012142A BR112017012142A2 BR 112017012142 A2 BR112017012142 A2 BR 112017012142A2 BR 112017012142 A BR112017012142 A BR 112017012142A BR 112017012142 A BR112017012142 A BR 112017012142A BR 112017012142 A2 BR112017012142 A2 BR 112017012142A2
Authority
BR
Brazil
Prior art keywords
breast cancer
therapeutic agents
predicting response
treating
treating breast
Prior art date
Application number
BR112017012142A
Other languages
English (en)
Inventor
Christian Peterson Amy
Uppal Hirdesh
Original Assignee
Medivation Prostate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Prostate Therapeutics Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of BR112017012142A2 publication Critical patent/BR112017012142A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

são fornecidos métodos para o tratamento de câncer de mama triplo negativo com um inibidor do receptor de androgênio, bem como métodos para o rastreio da probabilidade da eficácia de tal tratamento.
BR112017012142A 2014-12-12 2015-12-08 método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama BR112017012142A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462091195P 2014-12-12 2014-12-12
US201562142504P 2015-04-03 2015-04-03
US201562167110P 2015-05-27 2015-05-27
PCT/US2015/064500 WO2016094408A1 (en) 2014-12-12 2015-12-08 Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112017012142A2 true BR112017012142A2 (pt) 2018-01-02

Family

ID=55273509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012142A BR112017012142A2 (pt) 2014-12-12 2015-12-08 método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama

Country Status (15)

Country Link
US (3) US10196693B2 (pt)
EP (2) EP3604556A1 (pt)
JP (1) JP6735277B2 (pt)
KR (1) KR20170095306A (pt)
CN (1) CN107109488A (pt)
AU (1) AU2015360767A1 (pt)
BR (1) BR112017012142A2 (pt)
CA (1) CA2970469A1 (pt)
ES (1) ES2748005T3 (pt)
IL (1) IL252587A0 (pt)
MX (1) MX2017007707A (pt)
RU (1) RU2017120330A (pt)
SG (1) SG11201704425TA (pt)
WO (1) WO2016094408A1 (pt)
ZA (1) ZA201703904B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2739153T (pt) 2011-07-29 2018-11-28 Univ Colorado Regents Tratamento de cancro da mama
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
EP3604556A1 (en) 2014-12-12 2020-02-05 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
WO2016201299A1 (en) 2015-06-12 2016-12-15 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
KR101966493B1 (ko) * 2016-06-27 2019-04-05 국립암센터 삼중음성유방암 예후 예측용 바이오마커
KR101896558B1 (ko) * 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
US20200064556A1 (en) * 2017-04-26 2020-02-27 Nippon Telegraph And Telephone Corporation NxN Optical Switch
WO2018209341A1 (en) 2017-05-12 2018-11-15 Indiana University Research And Technology Corporation Precision medicine for treating and preventing suicidality
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
WO2020001473A1 (zh) * 2018-06-28 2020-01-02 复旦大学 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途
CN109735625A (zh) * 2019-03-18 2019-05-10 马榕 ***溢液在检测肿瘤相关基因中的应用
WO2024035653A1 (en) * 2022-08-06 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6937713B1 (en) 1999-12-30 2005-08-30 At&T Corp. IP call forward profile
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
US20070059720A9 (en) 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
BRPI0610359B8 (pt) 2005-05-13 2021-05-25 Univ California compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
US8445507B2 (en) 2006-03-27 2013-05-21 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
EP2664679B1 (en) 2008-05-30 2017-11-08 The University of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
BRPI1007990A2 (pt) 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
EP2425015B1 (en) 2009-04-29 2018-01-10 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
AU2010289448A1 (en) 2009-09-03 2012-03-22 The Scripps Research Institute Method for categorizing circulating tumor cells
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
US8781912B2 (en) 2011-03-15 2014-07-15 Opera Solutions, Llc Computer-based method and computer program product for setting floor prices for items sold at auction
CA2830240A1 (en) * 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
PT2739153T (pt) * 2011-07-29 2018-11-28 Univ Colorado Regents Tratamento de cancro da mama
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
JP6153613B2 (ja) 2012-08-23 2017-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート 乳がん治療を決定する方法
US9175291B2 (en) * 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) * 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
EP3604556A1 (en) 2014-12-12 2020-02-05 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
US11186876B2 (en) 2021-11-30
JP2018504892A (ja) 2018-02-22
WO2016094408A1 (en) 2016-06-16
JP6735277B2 (ja) 2020-08-05
ZA201703904B (en) 2019-12-18
EP3230471A1 (en) 2017-10-18
AU2015360767A1 (en) 2017-06-08
EP3604556A1 (en) 2020-02-05
MX2017007707A (es) 2018-03-06
ES2748005T3 (es) 2020-03-12
SG11201704425TA (en) 2017-06-29
CN107109488A (zh) 2017-08-29
KR20170095306A (ko) 2017-08-22
US20160168646A1 (en) 2016-06-16
RU2017120330A3 (pt) 2019-07-24
CA2970469A1 (en) 2016-06-16
US20220056541A1 (en) 2022-02-24
IL252587A0 (en) 2017-07-31
US20190169697A1 (en) 2019-06-06
US10196693B2 (en) 2019-02-05
RU2017120330A (ru) 2019-01-14
EP3230471B1 (en) 2019-08-28
US11952634B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
IL283733A (en) Methods for treating cancer using activated t cells
ZA201706616B (en) Method for treating cancer
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
MX2016001963A (es) Metodo de seleccion.
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL257691A (en) A method for treating cancer
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
BR112016018754A2 (pt) método de tratamento de um câncer com vascularização
PH12017501879A1 (en) Methods for treating cancer
MX2015011386A (es) Metodo para tratar cancer pancreatico.
NZ740817A (en) Pcna inhibitors
MX2015013021A (es) 5-bromo-indirrubinas.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
ZA201608820B (en) Method for treating drug resistant cancer
PT3265106T (pt) Novo método para tratamento e prognóstico do cancro
SG10201508795XA (en) Method for treating cancer
MX2016009541A (es) Metodo para tratar vajilla.
SG11201608328RA (en) Method for predicting response to therapy for cancer
EA201990411A1 (ru) Способы лечения рака предстательной железы
NZ779760A (en) Pcna inhibitors
TH182669B (th) วิธีการบำบัดโรคมะเร็งโดยการใช้ตัวยับยั้ง tigit และสารต้านโรคมะเร็ง

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MEDIVATION PROSTATE THERAPEUTICS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.